Liminatus Pharma Inc

Investors eye Liminatus Pharma’s sharp Nasdaq swings—stock close to a 52‑week low, a negative P/E and $37.6 M cap—indicating urgent strategy shifts to regain confidence.

Liminatus Pharma Inc, a healthcare company listed on the Nasdaq, is facing intense scrutiny due to its volatile financial performance, which has led to significant stock fluctuations and raised concerns about its long-term viability.

Liminatus Pharma Inc, a healthcare company listed on the Nasdaq, is facing significant financial challenges, including a dramatic stock price decline, negative price-to-earnings ratio, and reduced market capitalization, raising concerns about its st…

Liminatus Pharma Inc. is a pre-clinical-stage biopharmaceutical company pioneering a second-generation CD47 blockade antibody, IBA101, which shows promise in developing more effective and safer cancer therapies.

Liminatus Pharma Inc.’s stock price has experienced significant fluctuations, reaching a 52-week high of $16.44 and a 52-week low of $4.40, amidst a volatile biopharmaceutical sector.